{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:31Z","timestamp":1793405311713,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119251","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:06:42Z","timestamp":1774015602000},"page":"119251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2151-5586","authenticated-orcid":false,"given":"Sheraz A.","family":"Ditta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Christine","family":"Noordhoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-5080","authenticated-orcid":false,"given":"Franny","family":"Jongbloed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-6766","authenticated-orcid":false,"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J.","family":"Van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique E.M.M.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-7259","authenticated-orcid":false,"given":"Walter","family":"Taal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-7314","authenticated-orcid":false,"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119251_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119251_bib2","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.biopha.2026.119251_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102447","article-title":"Dabrafenib and trametinib administration in patients with <em>BRAF<\/em> V600E\/R or non-V600 <em>BRAF<\/em> mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial","volume":"69","author":"Shimoi","year":"2024","journal-title":"eClinicalMed."},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.biopha.2026.119251_bib5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK Inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"3","key":"10.1016\/j.biopha.2026.119251_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102968","article-title":"Mitochondrial dysfunction and calcium homeostasis in heart failure: exploring the interplay between oxidative stress and cardiac remodeling for future therapeutic innovations","volume":"50","author":"Johnson","year":"2025","journal-title":"Curr. Probl. Cardiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119251_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/CS20070430","article-title":"MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets","volume":"115","author":"Muslin","year":"2008","journal-title":"Clin. Sci. (Lond. )"},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"9992","key":"10.1016\/j.biopha.2026.119251_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119251_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2340\/1651-226X.2025.42567","article-title":"Cardiotoxicity in patients with metastatic melanoma treated with BRAF\/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility","volume":"64","author":"Oddershede","year":"2025","journal-title":"Acta Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119251_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119251_bib12","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","article-title":"Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study","volume":"11","author":"Ejerskov","year":"2023","journal-title":"Oncol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119251_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat. Med"},{"issue":"15","key":"10.1016\/j.biopha.2026.119251_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2026.119251_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119251_bib18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119251_bib19","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","article-title":"Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.78010","article-title":"Trametinib in adults with neurofibromatosis type 1 related symptomatic plexiform neurofibromas","volume":"99","author":"Noordhoek","year":"2026","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119251_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40272-022-00551-w","article-title":"Characterization of cardiac function by echocardiographic global longitudinal strain in a cohort of children with neurofibromatosis type 1 treated with selumetinib","volume":"25","author":"Caiffa","year":"2023","journal-title":"Paediatr. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib22","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1038\/s41598-020-68908-0","article-title":"Functional and morphological cardiovascular alterations associated with neurofibromatosis 1","volume":"10","author":"Cutruzzol\u00e0","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119251_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1067\/mhj.2002.122121","article-title":"The heart in neurofibromatosis type 1: an echocardiographic study","volume":"143","author":"Tedesco","year":"2002","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119251_bib24","article-title":"Hypertension in NF1: a closer look at the primacy of essential hypertension versus secondary causes","volume":"12","author":"Loponen","year":"2024","journal-title":"Mol. Genet Genom. Med."},{"issue":"41","key":"10.1016\/j.biopha.2026.119251_bib25","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.biopha.2026.119251_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00467-003-1397-5","article-title":"Blood pressure and cardiovascular involvement in children with neurofibromatosis type1","volume":"19","author":"Lama","year":"2004","journal-title":"Pedia Nephrol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119251_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090675","article-title":"Prevalence, type, and molecular spectrum of NF1 mutations in patients with neurofibromatosis type 1 and congenital heart disease","volume":"10","author":"Pinna","year":"2019","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.biopha.2026.119251_bib28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2026.119251_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084062","article-title":"Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis","volume":"390","author":"Gomes","year":"2025","journal-title":"BMJ"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:34:48Z","timestamp":1779244488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"alternative-id":["S0753332226002842"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119251","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicity of trametinib monotherapy in adults with neurofibromatosis type 1: Results from the TRAIN study","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119251"}}